Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Morgan Stanley India Investment Fund, Inc. (IIF)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
24.06-0.54 (-2.20%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close24.60
Open24.19
Bid24.07 x 800
Ask24.10 x 1100
Day's Range24.06 - 24.26
52 Week Range21.57 - 28.40
Volume198,985
Avg. Volume22,055
Market Cap258.57M
Beta (5Y Monthly)0.86
PE Ratio (TTM)3.28
EPS (TTM)7.33
Earnings DateN/A
Forward Dividend & Yield0.27 (1.10%)
Ex-Dividend DateDec 16, 2021
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for IIF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Morgan Stanley India Investment
    Analyst Report: Dr. Reddy's Laboratories LimitedHeadquartered in India, Dr. Reddy’s Laboratories develops and manufactures generic pharmaceutical products sold across the world. The company specializes in low-cost, easy-to-produce small-molecule generic drugs and active pharmaceutical ingredients. Its drug portfolio in recent years has included biosimilar drug launches in select emerging markets and has shifted toward injectables and more complex generic products. Geographically, the company’s sales are well dispersed across North America, India, and other emerging markets.
    Rating
    Fair Value
    Economic Moat
    2 months agoMorningstar
View more
Advertisement
Advertisement